Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes

Diabetes Care

Volumn 22, Issue SUPPL. 3, 1999, Pages

  Berger, Michael ^a   Jörgens, Viktor ^a   Mühlhauser, Ingrid ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ATHEROGENESIS; CARDIOTOXICITY; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINISM; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; METABOLIC REGULATION; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; VASCULAR DISEASE;

DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SULFONYLUREA COMPOUNDS; TEACHING;

EID: 0344141203     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus II. Mortality results. Diabetes 10 (Suppl. 2):785-830, 1970
2. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on non-fatal events treated with tolbutamide. Diabetes 23:1129-1152, 1976
3. The University Group Diabetes Program: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 31 (Suppl. 5):1-78, 1982
4. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 24 (Suppl. 1):65-184, 1975
5. Leibowitz G, Cerasi E: Sulfonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing. Diabetologia 39:503-314, 1996
6. Berger M, Mühlhauser I, Sawicki PT: Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mcllitus and coronary artery disease. Diabetologia 40:1492-1493, 1997 and 41:744, 1998
7. Berger M, Mühlhauser I, Sawicki PT: Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mcllitus and coronary artery disease. Diabetologia 40:1492-1493, 1997 and 41:744, 1998
8. Cleveland JC, Meldrum DR, Cain BS, Banerjeen A, Harken AH: Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 96:29-32, 1997
9. + channel blocker. Circulation 90:700-705, 1994
10. AIP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 94:2297-2301, 1996
11. Malmberg K for the DIGAMI Study Group: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314:1512-1515, 1997
12. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Johnson Nagel N, Comstock JP, Emanuele NV, Levin SR, Henderson W, Sook Lee H, VA CSDM Group: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 (VA CSDM). Diabetes Care 18:1113-1123, 1995
13. Ohkubo Y, Kishikawa H, Araki E: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with adult-onset diabetes. Diabetes Res Clin Pract 28:103-117, 1993
14. Vijan S, Hofer TP, Hayward RA: Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 127:788-795, 1997
15. Hofmann D, Opie LH: Potassium channel blockade and acute myocardial infarction: implications for management of the non-insulin requiring diabetic patients. Eur Heart J 14:1585-1589, 1993
16. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
17. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
18. Jarrett RJ: Why is insulin not a risk factor for coronary heart disease? Diabetologia 37:945-947, 1994
19. Gaster B, Hirsch IB: The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 158:134-140, 1998
20. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735-744, 1997
21. Sawicki PT, Berger M: Pharmacological treatment of diabetic patients with cardiovascular complications. J Intern Med 243:181-190, 1998
22. Pyörälä, K, Pedersen TR, Kjekshus J, Faegerman O, Olsson AG, Thorgeirsson G for the Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20:614-620, 1997
23. American Diabetes Association: Aspirin therapy in diabetes. Diabetes Care 21 (Suppl. 1):S45-S46, 1998
24. Ratzmann KP: Eine Analyse von alters-und geschlechts-spezifischer Diabetes-Prävalenz sowie Behandlkungsart: die Berlin-Studie. Akt Endokrin Stoffw 12:220-223, 1991
25. Ratzmann KP: Diabetologische Praxis. Mainz, Germany, Kirchheim, 1993
26. Berger M: To bridge science and patient care in diabetes. Diabetologia 39:749-757, 1996
27. Kronsbein P, Jörgens V, Mühlhauser I, Scholz V, Venhaus A, Berger M: Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet ii:1407-1411, 1988
28. Berger M, Jörgens V: Praxis der Insulintherapie. 6th ed. Berlin, Springer, 1995
29. Berger M: Diabetes Mellitus. München, Germany, Urban & Schwarzenberg, 1995
30. Davidson JK: Controlling diabetes mellitus with diet therapy. Postgrad Med J 59:114-122, 1976
31. Hadden DR, Blair ALT, Wilson EA: Natural history of diabetes presenting age 40-65 years: a prospective study of the influence of intensive dietary therapy. Q J Med 59:579-598, 1986
32. Ratzmann KP, Ilius A: Erfahrungen mit einem strukturierten Diät-Schulungsprogramm an frisch manifestierten Insulin-unabhängigen (Typ-II) Diabetikern. Z Klin Med 41:289-291, 1986
33. Berger M für die Arbeitsgruppe Strukturiertes Therapie und Schulungs-Programm für nicht-Insulin-behandelte Typ 2 Diabetiker: Diabetes-Behandlung in unserer Praxis: Behandlungs- und Schulungs-Programm für Typ 2 Diabetiker, die nicht Insulin spritzen. Köln, Germany, Deutscher Ärzte-Verlag, 1987
34. Grüsser M, Bott U, Ellermann P, Kronsbein P, Jörgens V: Evaluation of a structured treatment and teaching program for non-insulin treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 16:1268-1275, 1993
35. Berger M, Jörgens V, Flatten G: Health care for persons with non-insulin dependent diabetes mellitus: the German experience. Ann Intern Med 124:153-155, 1996
36. Mühlhauser I, Keim U, Hemmann D, Toelle M, Gösseringer G, Hansen I, Scholz V, Jorgens V, Berger M: Qualitätskontrolle der Langzeittherapie von älteren, insulinpflichtigen Diabetikem nach Teilnahme an einem stationȧren Diabetes-Behandlungs- und Schulungs-Programm. Z Klin Med 44:1221-1127, 1989
37. Berger M für die Arbeitsgruppe Strukturiertes Therapie und Schulungs-Programm für Insulin-behandelte Typ 2 Diabetiker: Behandlungs- und Schulungs-Programm für Typ 2 Diabetiker, die Insulin spritzen. Köln, Germany, Deutscher Ärzte-Verlag, 1989
38. Jörgens V, Hartmann P, Grüsser M: A model project in Germany: remuneration for physicians in ambulatory health care for providing a structured treatment and teaching programme for insulin treated type 2 diabetic patients. IDF Bull 41:37-38, 1996
39. Grüsser M, Hartmann P, Schlottmann, Jörgens V: Structured treatment and teaching programme for type 2 diabetic patients on conventional insulin treatment: evaluation of reimbursement policy. Patient Educ Couns 29:123-130, 1996
40. Müller UA, Müller R, Hunger-Dathe W, Schiel R, Jörgens V, Grüsser M: Should insulin therapy be started on an out-or inpatient basis? Results of a prospective controlled trial using the same teaching programme in ambulatory care and a university hospital. Diabėte Metabolism 24:251-255, 1998
41. UK Prospective Diabetes Study (UKPDS) Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998